Skip to content

Clinical observation on the Treatment of Endometriosis of Qi Deficiency and Blood Stasis Type with Qiling-Xiaozheng Formula

Clinical observation on the Treatment of Endometriosis of Qi Deficiency and Blood Stasis Type with Qiling-Xiaozheng Formula

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000122
Enrollment
Unknown
Registered
2025-01-15
Start date
2024-10-18
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometriosis

Interventions

Treatment group:Qiling-xiaozheng Formula

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1) Modern medical diagnosis of endometriosis accompanied by dysmenorrhea pelvic pain or dyspareunia and VAS = 3 cm; 2) TCM diagnosis of endometriosis-related pain with a syndrome type of qi deficiency and blood stasis; 3) Age = 18 years old not menopausal with a basically regular menstrual cycle (21 - 35 days); 4) Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1) Women who have received hormone therapy within 3 months before enrollment; 2) Women with other gynecological diseases such as sequelae of pelvic inflammatory disease or gynecological malignancies; 3) Women who are pregnant or lactating; 4) Women with severe primary diseases such as cardiovascular and cerebrovascular diseases liver kidney and hematopoietic system diseases or malignant tumors; women with mental disorders; women with a history of severe drug allergy or allergy to known drug components; 5) Women who are scheduled to undergo surgery or receive other treatment regimens in the near future; 6) Women who are currently participating in or have participated in other clinical trials within 3 months before this study.

Design outcomes

Primary

MeasureTime frame
VAS for endometriosis-related pain;

Secondary

MeasureTime frame
EHP-5;CMSS;Morisky Medication Adherence Scale;The efficacy of syndromes;Volume of endometriotic lesions;Serum CA125;EQ-5D-3L;

Countries

China

Contacts

Public ContactLiang Xuefang

Guangdong Provincial Hospital of Traditional Chinese Medicine 111 Dade Road Yuexiu District Guangzhou City Guangdong Province

liangxuefang@gzucm.edu.cn13926082916

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026